Industry News

FDA approves lacrimal duct balloon catheter

The U.S. Food and Drug Administration has approved the OphtaCath lacrimal duct balloon catheter from FCI Ophthalmics, according to a press release.

The OphtaCath achieves dilation of the lacrimal duct and treats the symptoms of epiphora, according to the release. It is a less invasive alternative to incisional procedures and eliminates the placement of tubes.

It is packaged in sterile 2-mm or 3-mm kits with one or two balloon catheters and a disposable inflation device.

The U.S. Food and Drug Administration has approved the OphtaCath lacrimal duct balloon catheter from FCI Ophthalmics, according to a press release.

The OphtaCath achieves dilation of the lacrimal duct and treats the symptoms of epiphora, according to the release. It is a less invasive alternative to incisional procedures and eliminates the placement of tubes.

It is packaged in sterile 2-mm or 3-mm kits with one or two balloon catheters and a disposable inflation device.